

Inflammation Before and After Implant Placement: Metabolic Context, Redox Balance, and Bone Healing

Osteoimmune control of wound repair, the effects of persistent metabolic inflammation and responsible pre-operative assessment



Core message: implant healing requires a timely inflammatory response followed by resolution, vascular repair and coordinated bone remodelling. Persistent inflammatory and metabolic stress may disturb this sequence, but risk must be interpreted from the whole clinical context.

Educational material for dental students, postgraduate trainees and academic teachers

Inflammation is part of healing

Implant placement creates a controlled wound. Blood contacts the implant surface, proteins adsorb within seconds, coagulation and complement pathways become active, and innate immune cells enter the surgical site. This early response is not a complication; it prepares the environment for debridement, angiogenesis and tissue reconstruction.

Controlled acute response	Persistent dysregulated response
Begins rapidly after surgical injury.	Continues beyond the period needed for repair.
Supports removal of debris and microbial control.	Maintains cytokine and proteolytic activity.
Promotes vascular ingrowth and recruitment of progenitor cells.	Can impair vascular function and cellular metabolism.
Transitions toward resolution and matrix formation.	Delays the transition to repair and remodelling.
Allows balanced osteoblast and osteoclast activity.	May shift remodelling toward resorption or poor-quality repair.

Resolution is an active phase

Successful healing does not simply require fewer inflammatory mediators. It requires a coordinated change in cell phenotype and signalling. Neutrophil recruitment declines, macrophages clear debris and apoptotic cells, pro-resolving pathways become dominant, and stromal and vascular cells rebuild the tissue environment.

Inflammation cannot be reduced to on or off

The goal is neither complete suppression nor uncontrolled activation. An inadequate early response can impair wound defence, while excessive or persistent activation can damage tissue. Timing, magnitude and resolution are more informative than the presence of inflammation alone.

The biological target is a well-sequenced response: haemostasis, early inflammation, resolution, tissue formation and remodelling.

The healing sequence around an implant

Phase	Approximate period	Principal events	Potential disruption
Haemostasis	Minutes to first day	Clot formation, fibrin matrix, platelet activation and provisional stability.	Excessive bleeding, poor clot stability or severe vascular compromise.
Early inflammation	First several days	Neutrophil and monocyte recruitment, debris clearance and cytokine signalling.	Persistent infection, excessive trauma or dysregulated host response.
Proliferation and tissue formation	Days to weeks	Angiogenesis, fibroblast activity, osteogenic differentiation and osteoid formation.	Hypoxia, hyperglycaemia, smoking, malnutrition or continued inflammation.
Remodelling	Weeks to months and beyond	Coupled osteoclast and osteoblast activity; maturation of peri-implant bone.	Micromotion, overload, chronic inflammation or poor maintenance.

Primary and secondary stability

Primary stability is mechanical and depends on implant geometry, surgical preparation and local bone conditions. Secondary stability develops biologically as new bone forms and remodels at the interface. During the transition, excessive micromotion can disrupt repair even when systemic health is favourable.

Local conditions remain central

Biofilm control, atraumatic technique, three-dimensional implant position, prosthetic design and loading conditions directly influence the wound. A systemic inflammatory background does not replace these explanations and should not be used to excuse correctable local factors.

Time windows are approximate

Healing phases overlap and vary with site, procedure, grafting, implant surface and patient factors. Calendar time alone does not prove biological readiness for loading.

Osseointegration is both mechanical and biological. Stable fixation protects the developing tissue, while osteoimmune signalling guides its formation and remodelling.

Osteoimmunology at the bone-implant interface

Bone and immune cells operate within one regulatory network. Immune cells influence osteogenic progenitors, osteoblasts and osteoclasts; bone cells in turn produce signals that regulate immune-cell recruitment and function.

Cell population	Role during healing	Risk when dysregulated
Neutrophils	Early antimicrobial defence, debris clearance and signalling.	Persistent activation can prolong proteolytic and oxidative injury.
Monocytes and macrophages	Phagocytosis, orchestration of inflammation, resolution, angiogenesis and repair.	Failure to transition toward reparative functions can sustain inflammation.
T lymphocytes and regulatory cells	Adaptive regulation and cytokine control of bone-cell pathways.	Excess pro-resorptive signalling may support osteoclastogenesis.
Mesenchymal progenitors	Differentiate toward osteogenic and other stromal lineages.	Metabolic and oxidative stress can impair osteogenic commitment.
Osteoblast-lineage cells	Produce osteoid, regulate mineralization and control osteoclast signals.	Reduced differentiation or function delays new bone formation.
Osteoclasts	Remove damaged bone and enable coupled remodelling.	Excess or uncoupled activity contributes to net bone loss.

Macrophage phenotypes are a spectrum

The familiar M1/M2 model is useful for illustrating inflammatory and reparative tendencies, but real macrophage states are more diverse and change over time. Successful repair depends on appropriate sequencing and plasticity rather than a permanent switch to one phenotype.

Osteoimmune balance is dynamic. The same cell population may support defence, repair or resorption depending on timing and local signals.

Coupled bone remodelling and the RANKL-OPG axis

Osseointegration does not require bone formation alone. Damaged bone must be removed, new woven bone deposited and later remodelled into a load-adapted structure. Osteoclast and osteoblast activity must therefore remain coupled.

RANKL and osteoprotegerin

RANKL binds RANK on osteoclast precursors and promotes their differentiation and activity. Osteoprotegerin acts as a decoy receptor that limits RANKL signalling. The local balance is influenced by osteoblast-lineage cells, osteocytes, immune cells, mechanical loading and inflammatory cytokines.

Signal or condition	Expected direction	Interpretive caution
IL-1 beta and TNF-alpha	Can enhance inflammatory osteoclast pathways.	Local concentration and timing determine biological effect.
IL-6 family signalling	Participates in immune and bone-cell communication.	May have context-dependent and pathway-specific effects.
Mechanical loading	Supports adaptation within a physiological range.	Excess load and micromotion can disrupt immature repair.
RANKL/OPG relationship	Higher effective RANKL signalling favours osteoclastogenesis.	A fluid biomarker ratio does not directly measure net bone balance.
Osteoblast function	Supports osteoid production and coupling signals.	Cell number alone does not establish mineralized bone quality.

Marginal bone loss has multiple pathways

Persistent plaque-associated inflammation is a major driver of peri-implantitis, but early remodelling, surgical trauma, implant position, tissue dimensions and loading can also affect marginal bone. A single cytokine or radiographic observation should not be assigned one cause without longitudinal and clinical context.

Resorption is not inherently pathological. Osteoclast activity is necessary for repair; pathology develops when resorption becomes excessive, persistent or uncoupled from formation.

Redox balance in bone repair

Reactive oxygen species are produced during mitochondrial metabolism and immune-cell activity. At controlled levels they function as signalling molecules. Oxidative stress develops when oxidant production exceeds the capacity of antioxidant and repair systems.

Redox context	Cellular effect	Potential consequence
Physiological ROS signalling	Supports antimicrobial defence and intracellular repair signalling.	Normal progression through early wound healing.
Persistent excess ROS	Damages proteins, lipids, nucleic acids and mitochondrial function.	Reduced cell viability and delayed tissue formation.
Osteoblast-lineage stress	May reduce differentiation, matrix production and mineralization.	Slower development of secondary stability.
Osteoclast pathway activation	Can support differentiation and resorptive activity in inflammatory settings.	Shift toward net bone resorption.
Progenitor-cell dysregulation	May impair osteogenic commitment and favour alternative lineage pathways.	Lower regenerative capacity.

Antioxidants are not a universal treatment

Endogenous antioxidant systems, nutritional status, physical activity and metabolic control influence redox balance. However, mechanistic evidence does not justify routine high-dose antioxidant supplementation for implant patients. Supplements can have adverse effects and should not substitute for treatment of diabetes, smoking, infection or nutritional deficiency.

Oxidative stress is difficult to measure clinically

Many proposed markers are sensitive to collection, storage and systemic conditions. No single chairside redox test currently defines implant healing potential or determines whether surgery should proceed.

Redox biology is dose- and time-dependent. Reactive oxygen species can support signalling at physiological levels and damage tissue when production becomes excessive or prolonged.

Metainflammation as a biological framework

Metainflammation describes persistent low-grade immune activation associated with metabolic dysfunction and chronic nutrient excess. It is a mechanistic framework rather than a stand-alone dental diagnosis. Adipose tissue, liver, skeletal muscle, vascular endothelium and circulating immune cells can all contribute to the systemic environment.

Metabolic context	Potential pathway relevant to healing	Evidence boundary
Type 2 diabetes and hyperglycaemia	Advanced glycation, microvascular dysfunction, altered immune response and impaired bone-cell activity.	Risk varies with glycaemic control, comorbidity and study design.
Obesity and adipose dysfunction	Adipokine imbalance, insulin resistance and low-grade inflammatory signalling.	Obesity alone does not consistently predict implant failure.
Dyslipidaemia	Oxidized lipids, endothelial effects and oxidative stress may influence bone metabolism.	Much mechanistic evidence is preclinical; direct clinical thresholds are lacking.
Metabolic liver disease	Shares insulin resistance, lipid dysregulation and inflammatory pathways.	Implant-specific clinical evidence remains limited.
Chronic stress and sleep disruption	Neuroendocrine, behavioural and metabolic pathways may modify immunity and self-care.	Associations are multifactorial and difficult to isolate.

Shared risk does not prove a direct pathway

Metabolic disorders can cluster with smoking, periodontitis, medication use, diet, socioeconomic factors and reduced maintenance attendance. These shared determinants complicate causal interpretation. A patient-level association does not show that circulating inflammation directly caused one implant outcome.

Metainflammation modifies context; it does not replace local diagnosis. Plaque, infection, implant position, prosthetic access and loading still require direct assessment.

Systemic conditions and implant outcomes

Diabetes

Diabetes is not an automatic contraindication to implant therapy. Evidence supports attention to current glycaemic control, complications, medications and maintenance capacity. Poor control is biologically and clinically more concerning than the diagnostic label alone. Coordination with the treating physician may be appropriate when control is uncertain or treatment is unstable.

Obesity and metabolic syndrome

Obesity may be associated with peri-implant inflammatory measures in some studies, yet a recent meta-analysis did not find a statistically significant increase in implant failure. Heterogeneity was substantial. Body mass index alone should not determine candidacy; the broader metabolic and behavioural profile is more informative.

Dyslipidaemia and metabolic liver disease

Mechanistic research links oxidized lipids and chronic metabolic inflammation with altered bone biology. Direct evidence that lipid values or liver disease markers independently predict implant failure remains insufficient for universal thresholds.

Vitamin D

Vitamin D participates in mineral metabolism and immune regulation, but routine screening or supplementation solely to improve implant outcomes is not established for every patient. Testing is best based on medical indications, risk of deficiency and local practice standards.

Smoking

Smoking affects vascular function, immune responses and wound healing and remains a modifiable concern. Support for cessation should be integrated into risk reduction rather than framed as a guarantee of success or failure.

Avoid	Use instead
"This disease prevents osseointegration."	"Current control and associated complications may modify healing risk."
"An elevated inflammatory marker explains the failure."	"The result is nonspecific and must be integrated with local and medical findings."
"Normal blood tests guarantee safe healing."	"Normal values do not exclude local, mechanical or behavioural risk."
"Metabolic optimization eliminates implant risk."	"Optimization reduces modifiable risk but cannot remove all uncertainty."

Pre-operative assessment and risk modification

Start with history and oral diagnosis

Review diabetes control, cardiovascular and metabolic conditions, smoking, medication, previous healing problems and current medical care. Examine periodontal stability, biofilm, caries, endodontic infection, mucosal disease, prosthetic cleansability and planned implant position.

Step	Action	Reason
1. Identify active local disease	Treat periodontitis, acute infection and uncontrolled plaque before elective implant surgery.	Reduces direct microbial and inflammatory exposure.
2. Assess systemic stability	Clarify current diagnoses, control, medication and relevant complications.	Determines whether medical coordination or postponement is appropriate.
3. Order targeted tests when indicated	Use HbA1c, blood count, CRP, lipids, vitamin D or other tests only when supported by history, medical indication or coordinated care.	Avoids indiscriminate screening and false certainty.
4. Optimize modifiable factors	Support smoking cessation, metabolic control, nutrition, sleep, hygiene and maintenance.	Improves the overall healing environment and long-term care.
5. Adapt the surgical and recall plan	Match invasiveness, staging, loading and follow-up to combined local and patient risk.	Reduces avoidable stress and improves surveillance.

Antibiotics are not a treatment for metainflammation

CBC-derived indices, CRP or metabolic risk alone do not create an indication for prophylactic or therapeutic antibiotics. Antimicrobial decisions should follow procedure-specific guidance, infection status, patient factors and antimicrobial-stewardship principles.

Post-operative interpretation

Pain, swelling and inflammatory markers change after surgery. Interpret the time course, wound findings and systemic symptoms rather than a single value. Persistent or worsening signs require evaluation for infection, mechanical instability, tissue injury or other complications.

Targeted assessment is preferable to a universal laboratory panel. Tests should answer a defined clinical question and lead to an actionable decision.

Clinical synthesis and selected references

Clinical and biological synthesis

- Early inflammation is necessary for wound defence and initiation of repair.
- Resolution and transition toward vascular and osteogenic repair are active biological processes.
- Osseointegration depends on coordinated immune, vascular, osteoblast and osteoclast functions.
- Excess oxidative and metabolic stress may impair healing, but clinical risk is multifactorial.
- Diabetes, obesity and dyslipidaemia should be interpreted through current control and associated complications.
- Local infection, biofilm, implant stability, position and loading remain essential explanations for complications.
- Laboratory testing should be targeted to the medical history and an actionable clinical question.

Selected references

1. Albrektsson T, Wennerberg A. On osseointegration in relation to implant surfaces. Foundational concepts of bone-implant integration and remodelling.
2. Trindade R, Albrektsson T, Tengvall P, Wennerberg A. Foreign body reaction to biomaterials: on mechanisms for build-up and breakdown of osseointegration. *Clinical Implant Dentistry and Related Research*. 2016.
3. Wang J, et al. Osteoimmunology drives dental implant osseointegration: a new paradigm for implant dentistry. 2021. PMID: 33737990.
4. Osteoimmune regulation underlies oral implant osseointegration and its perturbation. 2023. PMID: 36761175.
5. Innate immune regulation in dental implant osseointegration. 2024. PMID: 38346728.
6. Macrophages in the process of osseointegration around the implant and their regulatory strategies. 2024. PMID: 38166507.
7. Navigating oxidative stress in oral bone regeneration: mechanisms and reactive oxygen species-regulating biomaterial strategies. 2025. PMID: 41048977.
8. Adipose tissue dysfunction: impact on bone and osseointegration. 2021. PMID: 34374815.
9. Diabetes mellitus and dental implants: a systematic review and meta-analysis. 2022. PMID: 35591561.
10. Systematic review on diabetes mellitus and dental implants: an update. 2022. PMID: 34978649.
11. Impact of obesity on dental implant failure and peri-implant health: a systematic review and meta-analysis. 2026. PMID: 41692721.
12. Osteoimmune regulation in dental implant osseointegration: from foreign body response to therapeutic immunomodulation. 2026. PMID: 41878121.

Educational use and limitations

This material presents biological mechanisms and evidence-calibrated principles for implant assessment. It does not replace individual medical evaluation, laboratory interpretation or procedure-specific clinical guidance.

Funding statement

This work was co-funded by the European Union under grant agreement No. 2024-1-PL01-KA220-HED-000251208. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the Foundation for the Development of the Education System (FRSE). Neither the European Union nor FRSE can be held responsible for them.